drugset
drugset / Trial / NCT07328542

Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men

NCT07328542 ↗

Phase 4 Not yet recruiting 144 enrolled Azurity Pharmaceuticals CBCC Global Research · collab
NaSingle-groupOpen-labelTreatment

Summary

A Phase 4, multi-center, open-label, single-arm 24-hour Ambulatory Blood Pressure Monitoring (ABPM) study of Testosterone Cypionate Injection in Hypogonadal Men to assess change in 24-hour ambulatory blood pressure from Baseline to End of Treatment

Timeline

Start
2026-02
Primary completion
2027-06
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Cypionate Small molecule 200 mg/ml Intramuscular

Indications

hypogonadism, male